The effectiveness of pharmacological agents for the treatment of uveitic macular oedema (UMO): a systematic review

Research output: Contribution to journalArticle

Colleges, School and Institutes

Abstract

Purpose: To conduct a systematic review of effectiveness of pharmacological therapies for treatment of Uveitic Macular Edema (UMO).

Method/Design: Comparative studies of pharmacological therapies in patients with UMO were identified in Cochrane CENTRAL/MEDLINE/EMBASE/CINAHL/trials registers (February 2017). PROSPERO registration: CRD42015019170.

Results: Thirty-one studies were included. Corticosteroids were the most frequently studied (n = 20). Corticosteroids (all forms) were consistently of greater/equal efficacy to active comparators; for anti-VEGF (n = 4) improvement, best-corrected visual acuity (BCVA) and central macular thickness (CMT) were mostly less than local corticosteroid injection; for interferon (n = 1) improvement BCVA and CMT were greater than the comparator of methotrexate; for topical indomethacin (n = 1) improvement, BCVA and CMT were greater than placebo. Non-steroidal anti-inflammatory drugs, carbonic anhydrase inhibitors, and vitamin E (n = 5) were not effective for these outcomes.

Conclusion: The review highlights areas where the evidence base is still lacking, and appropriately focused trials are needed to inform best treatment to tackle this sight-threatening condition.

Details

Original languageEnglish
Pages (from-to)658-680
Number of pages23
JournalOcular immunology and inflammation
Volume27
Issue number4
Publication statusPublished - 19 May 2019

Keywords

  • Systematic review, macular oedema, macular edema, uveitis, management, pharmacological agents, treatment, meta-analysis, Macular edema, systematic review

ASJC Scopus subject areas